Cancer-faking travel agent jailed for conning clients out of £2,600,000

  • 📰 MetroUK
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 82%

United Kingdom Headlines News

United Kingdom Latest News,United Kingdom Headlines

BREAKING: A travel agent who claimed she had cancer while defrauding friends, family and hundreds of customers, who bought holidays from her in a £2.6 million con, has been jailed for nine years.

A travel agent who claimed she had cancer while defrauding friends, relatives and more than 1,400 customers in a £2.6 million con has been jailed for nine years.

She sold luxury holidays at knock-down prices, offering deals such as a five star all-inclusive week in Dubai for just £500, but was funding the sales in a ponzi-style scheme by bringing in new customers to fund existing ones. Barlow admitted theft of £500,000 from one person, 10 counts of fraud and a money laundering charge totalling £1,688,220.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 13. in UK

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Aspirin increases chemosensitivity of colorectal cancer cells and inhibits the expression of toll-like receptor 4 - Cancer Cell InternationalBackground Chemotherapy resistance is an important bottleneck affecting the efficacy of chemotherapy in colon cancer. Therefore, improving the chemotherapy sensitivity of colorectal cancer cells is of great significance for improving the prognosis of patients with colon cancer. Methods CCK-8 assay was employed to examine the cell viability of colorectal cancer cell lines. Realtime-PCR and western blot were used to explore toll-like receptor 4 (TLR4) expression in colorectal cancer cell lines. The functions of TLR4 in the stemness of the colorectal cancer cell lines were analyzed by infecting cells with lentivirus containing TLR4 siRNA. Results We found that aspirin could effectively enhance the chemosensitivity of CT26 and HCT116 colorectal cancer cell lines. Aspirin can also inhibit the stemness of colorectal cancer cell including inhibiting the number of clone formation and reducing the volume and number of cell spheres and inducing the down-regulation of stemness-related genes. Besides that, aspirin also lead to down-regulation of TLR4 expression in colorectal cancer cells. The TLR4 positive colorectal cancer cells demonstrated a higher chemotherapy resistance potential than TLR4 negative colorectal cancer cells. In addition, the stemness of TLR4 positive colorectal cancer cells is stronger than TLR4 negative colorectal cancer cells. Conclusion The results of our study indicate that aspirin increases chemosensitivity of colorectal cancer cells and inhibits the expression of toll-like receptor 4.
Source: BioMedCentral - 🏆 22. / 71 Read more »

Northern Ireland conservation: More than 100 species added to priority listThe kingfisher and bog orchid join almost 600 other NI species highlighted for conservation.
Source: BBCNewsNI - 🏆 95. / 52 Read more »

Northern Ireland conservation: More than 100 species added to priority listThe kingfisher and bog orchid join almost 600 other NI species highlighted for conservation.
Source: BBCScienceNews - 🏆 87. / 53 Read more »

Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years - Breast Cancer ResearchBackground Breast cancer (BC) grading plays a critical role in patient management despite the considerable inter- and intra-observer variability, highlighting the need for decision support tools to improve reproducibility and prognostic accuracy for use in clinical practice. The objective was to evaluate the ability of a digital artificial intelligence (AI) assay (PDxBr) to enrich BC grading and improve risk categorization for predicting recurrence. Methods In our population-based longitudinal clinical development and validation study, we enrolled 2075 patients from Mount Sinai Hospital with infiltrating ductal carcinoma of the breast. With 3:1 balanced training and validation cohorts, patients were retrospectively followed for a median of 6 years. The main outcome was to validate an automated BC phenotyping system combined with clinical features to produce a binomial risk score predicting BC recurrence at diagnosis. Results The PDxBr training model (n = 1559 patients) had a C-index of 0.78 (95% CI, 0.76–0.81) versus clinical 0.71 (95% CI, 0.67–0.74) and image feature models 0.72 (95% CI, 0.70–0.74). A risk score of 58 (scale 0–100) stratified patients as low or high risk, hazard ratio (HR) 5.5 (95% CI 4.19–7.2, p | 0.001), with a sensitivity 0.71, specificity 0.77, NPV 0.95, and PPV 0.32 for predicting BC recurrence within 6 years. In the validation cohort (n = 516), the C-index was 0.75 (95% CI, 0.72–0.79) versus clinical 0.71 (95% CI 0.66–0.75) versus image feature models 0.67 (95% CI, 0.63–071). The validation cohort had an HR of 4.4 (95% CI 2.7–7.1, p | 0.001), sensitivity of 0.60, specificity 0.77, NPV 0.94, and PPV 0.24 for predicting BC recurrence within 6 years. PDxBr also improved Oncotype Recurrence Score (RS) performance: RS 31 cutoff, C-index of 0.36 (95% CI 0.26–0.45), sensitivity 37%, specificity 48%, HR 0.48, p = 0.04 versus Oncotype RS plus AI-grade C-index 0.72 (95% CI 0.67–0.79), sensitivity 78%, specificity 49%, HR 4.6, p | 0.001 versus Oncotype
Source: BioMedCentral - 🏆 22. / 71 Read more »

Brave Scots mum lost voice box and food pipe as earache turned out to be cancerJulie Baker, 50, was first told the pain was an infection in February 2022 - but after further tests she was diagnosed with throat cancer.
Source: Daily_Record - 🏆 9. / 89 Read more »

More than 100 bikers make final wish come true for terminally ill manDavid Wildman, from Colne, received the devastating diagnosis of terminal cancer in 2022
Source: LiveLancs - 🏆 10. / 87 Read more »